Search


Current filters:




Clear current filters  or Add more filters

View Option



Results 11-20 of 32 (Search time: 0.004 seconds).

  Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG) (Journal article)

  Near-absolute expression of the bcl-2 protein identifies a subgroup of stage II breast cancer patients with a most favorable outcome. Results of a clinicopathological study (Journal article)

  Diagnostic and therapeutic management of cancer of an unknown primary (Journal article)

  Targeting c-KIT, PDGFR in cancer of unknown primary: a screening study for molecular markers of benefit (Journal article)

  Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review (Journal article)

  Tumor volumetry as predictive and prognostic factor in the management of ovarian cancer (Journal article)

  Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression (Journal article)

  Brain metastasis of unknown primary: a diagnostic and therapeutic dilemma (Journal article)

  Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial (Journal article)

  Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer (Journal article)